How did INM's Q1 2025 EPS performance compare to expectations?

InMed Pharmaceuticals Inc. (NASDAQ: INM) did not report any EPS in Q1 2025, which makes direct comparison with expectations challenging. However, the company's Q2 2025 EPS was reported as -$3.64, which is significantly lower than the EPS of -$3.71 recorded in the same period last year. This indicates a decline in the company's financial performance, which may have been unexpected by investors, especially considering the steady progress in their pharmaceutical pipeline and commercial operations as reported by the company. The net loss of $2.58 million for the quarter ending December 31, 2024, compared to a net loss of $1.48 million for the same period in 2023, also suggests a worsening financial trend. Despite this, the company secured $1.43 million from private placements during the quarter, providing some financial relief.